FDA labeling rules for drugs and biologics
A human drug or biological product may be presented only for the uses in its approved or permitted labeling, and that labeling must be informative and accurate and neither promotional in tone nor false or misleading in any particular.1 An advertisement for a prescription drug covered by an approved new drug application may not recommend or suggest any use that is absent from the labeling accepted in that application or supplement.2 On the container itself, Part 201 requires the identity of the drug, the net quantity of contents, ingredient information, the name and place of business of the manufacturer, packer or distributor and, for prescription products, the statement “Rx only” with dosage and route.1 The detailed directions sit in the prescribing information for prescription products and in the Drug Facts panel for nonprescription products.1
Label, labeling and intended use
The label is the matter on the immediate container and, where applicable, the outer package. Labeling reaches further. The following are determined to be labeling under section 201(m) of the act when they are descriptive of a drug and disseminated by or on behalf of its manufacturer, packer or distributor.2
- brochures
- booklets
- mailing pieces
- detailing pieces
- file cards
- bulletins
- price lists
- catalogs
- letters
- motion picture films
- sound recordings
- exhibits
- literature
- reprints
References published for use by practitioners that contain drug information supplied by the firm fall in the same category.2
Intended use is defined by objective intent, shown by the expressions of the persons legally responsible for the labeling, by the design or composition of the article or by the circumstances of distribution.1 Labeling claims, advertising matter and oral or written statements by those persons or their representatives are examples.1 A firm is not regarded as intending an unapproved new use for an approved drug based solely on its knowledge that health care providers were prescribing the drug for that use.1 Intended use can change after introduction into interstate commerce. A packer, distributor or seller who intends the article for different uses must supply labeling for the new intended uses.1
Adequate directions for use and the exemptions
Adequate directions for use means directions under which the layman can use a drug safely and for the purposes for which it is intended.1 Directions may be inadequate through omission or incorrect specification of any of the following.1
- the conditions and purposes for which the drug is intended
- the quantity of dose
- the frequency
- the duration
- the time of administration
- the route or method
- any preparation such as shaking or dilution
Statements of intended conditions exclude uses for which the drug can be safely used only under the supervision of a licensed practitioner and for which it is advertised solely to such practitioners.1
A prescription drug subject to section 503(b)(1) is exempt from section 502(f)(1) when the conditions in § 201.100 are met, which include possession by a manufacturer, wholesaler, pharmacy, public health agency or licensed practitioner and dispensing in accordance with section 503(b).1 Two further exemptions operate on their own terms. A drug is exempt insofar as adequate directions for its common uses are known to the ordinary individual.1 A harmless drug ordinarily used as an inactive ingredient is exempt. The exemption does not reach a substance intended for a use that results in the preparation of a new drug unless an approved application provides for that use.1 Examples of such inactive ingredients are the following.
- a coloring
- an emulsifier
- an excipient
- a flavoring
- a lubricant
- a preservative
- a solvent
What the prescription drug label must bear
Under § 201.100(b) the label of a prescription drug bears the statement “Rx only”, the recommended or usual dosage and the route of administration where the product is not for oral use.1 It bears the quantity or proportion of each active ingredient together with the information required by section 502(d) and (e).1 For products other than oral, the names of all inactive ingredients appear, with allowances for flavorings, perfumes, color additives and trace identification substances.1 For parenteral injections the quantity or proportion of all inactive ingredients is required, with pH adjusters and tonicity agents declarable by name and effect and with water for injection not needing to be named.1 The label also bears an identifying lot or control number and a statement to the pharmacist specifying the container type for dispensing.1
The label of a prescription or insulin-containing drug in package form bears a statement of identity in terms of the established name as one of its principal features, and a declaration of net quantity of contents expressed by weight, measure, numerical count or a combination.1 Unit dosage forms are counted, solids are stated by weight, liquids by fluid measure and designated medical gases by volume measure.1 Where dosage varies within wide limits, FDA takes the view that a statement such as “See package insert for dosage information” satisfies § 201.100(b)(2), and the regulation adds that an informative dosage statement should appear on the label where one can readily be set out.1 The expiration date, where required, appears on the immediate container and the outer package unless it is legible through that package. An allowance applies to single-dose containers packed in individual cartons.1
Content and format of prescribing information
Prescription drug labeling described in § 201.100(d) must contain a summary of the essential scientific information needed for the safe and effective use of the drug and must be updated under §§ 314.70 and 601.12 when new information makes it inaccurate or misleading.1 It must be based whenever possible on data derived from human experience, and conclusions drawn from animal data must be identified as such.1
Two formats exist. The Highlights format in § 201.56(d) and § 201.57 applies to products with an NDA, BLA or efficacy supplement approved between 30 June 2001 and 30 June 2006, pending on 30 June 2006 or submitted on or after that date.1 Highlights opens with the verbatim limitation statement directing the reader to the full prescribing information, followed by the proprietary and established or proper name, the dosage form, the route of administration and any controlled substance symbol.1 The four-digit year of initial U.S. approval appears immediately beneath the established or proper name.1 A boxed warning summary of no more than 20 lines appears in a bolded box under an upper-case heading containing the word “WARNING”, followed by the verbatim sentence referring the reader to the complete boxed warning.1 Recent major changes are listed by section.1
Products outside § 201.56(b)(1) follow § 201.56(e) and § 201.80.1 That older format uses the section headings listed in § 201.56(d) in order, beginning with Description and Clinical Pharmacology.1 The Description section carries the proprietary and established names, the dosage form and route, the qualitative and quantitative ingredient information required by § 201.100(b), a sterility statement where applicable, the pharmacological or therapeutic class, the chemical name and structural formula and, for radioactive products, the principal nuclear physical characteristics.1
Nonprescription drug labeling
The principal display panel is the part of the label most likely to be examined under customary conditions of display for retail sale, and it must accommodate all mandatory information without crowding or obscuring designs.1 Where a package bears alternate principal display panels, the required information is duplicated on each.1 The statement of identity uses the established name followed by the general pharmacological category or principal intended action, in bold face type, placed in direct conjunction with the most prominent display of the proprietary name.1 Indications for use belong in the directions for use.1 The net quantity declaration follows § 201.62 and is augmented where needed to distinguish strengths.1
Section 201.66 sets the Drug Facts content and format requirements for the labeling of all OTC drug products. Where an applicable monograph or regulation contains conflicting content and format requirements, § 201.66 controls unless the monograph or regulation specifically provides otherwise.1 OTC products intended for systemic absorption carry the warning “If pregnant or breast-feeding, ask a health professional before use.”, with the first four words in bold type.1 A product-specific warning established in an NDA or a final monograph replaces it.1 Products intended to benefit the fetus or nursing infant and products labeled exclusively for pediatric use are exempt, and other exemptions may be sought by petition under § 10.30.1 Orally or rectally administered aspirin products carry the additional third-trimester warning in § 201.63(e).1
A nonprescription product approved with an additional condition for nonprescription use is exempt from section 502(f)(1) only if its label carries the ACNU Instructions and the ACNU Statement in § 201.130, or FDA-approved alternative wording supported by data on consumer understanding.1 Where the purpose of the ACNU is self-selection the instructions appear first under the “Use” or “Uses” heading, and where the purpose is actual use they appear first under “Directions”.1 The statement about the ACNU appears on the principal display panel and on the immediate container surface the consumer is most likely to view.1
Prominence, language and specific disclosures
Required statements can fail the prominence test in section 502(c) through placement away from the panel displayed at purchase, small or crowded type, insufficient background contrast or obscuring designs.1 Exemptions that depend on insufficiency of label space do not apply where the insufficiency is caused by non-required matter, by giving more conspicuousness than section 502(c) requires or by a representation in a foreign language.1 Required information must appear in English, with an exception for articles distributed solely in Puerto Rico or in a Territory where the predominant language is other than English.1
Products administered orally, nasally, rectally or vaginally or used in the area of the eye that contain FD&C Yellow No. 5 must declare it by the names FD&C Yellow No. 5 and tartrazine.1 Prescription products in those routes carry the tartrazine sensitivity warning in the Precautions section of the § 201.100(d) labeling.1 The parallel declaration for FD&C Yellow No. 6 on OTC labels in § 201.20(c) was suspended pending further agency action at 53 FR 49138 of 6 December 1988.1
Bar code requirements reach manufacturers, repackers, relabelers and private label distributors that are subject to registration and listing under section 510.1 Prescription drug products, biological products and OTC drug products dispensed pursuant to an order and commonly used in hospitals must bear the bar code.1 The following are outside the requirement.1
- samples
- allergenic extracts
- intrauterine contraceptive devices regulated as drugs
- medical gases
- radiopharmaceuticals
- low-density polyethylene form fill and seal containers without an overwrap
The bar code contains at least the NDC number in a linear bar code meeting EAN/UCC or HIBCC standards or another format approved by the relevant Center Director, surrounded by sufficient blank space and remaining intact in normal use.1
What may be claimed
Labeling may make no implied claim or suggestion of drug use where there is inadequate evidence of safety or a lack of substantial evidence of effectiveness.1 A false or misleading representation about another drug, a device, a food or a cosmetic misbrands the drug.1 Naming a multi-ingredient drug after some but not all of its ingredients can be misleading even where the full list appears elsewhere in the labeling.1 Ingredient presentation can also mislead through the order or prominence of names, through failure to reveal a material proportion, through a fanciful proprietary name implying unique effectiveness for a common substance or through featuring inert ingredients so as to suggest a value greater than their functional role.1
Prescription drug advertisements must present a true statement of information in brief summary relating to side effects, contraindications and effectiveness.2 The requirement applies to the entire advertisement, so true information in one distinct part does not cure untrue or misleading material elsewhere.2 Fair balance is required, and an advertisement fails the true statement test if effectiveness information is given in greater scope, depth or detail than section 502(n) requires without a comparable summary of side effects and contraindications.2 Section 202.1(e)(6) lists representations that render an advertisement false or misleading, including unsupported superiority claims, out-of-context quotations and nonclinical data presented as clinically significant.2 Broadcast advertisements must include a major statement of major side effects and contraindications, and must either contain the brief summary or make adequate provision for dissemination of the approved labeling.2 For television and radio advertisements directed to consumers the major statement must be presented in a clear, conspicuous and neutral manner, which in television format requires concurrent audio and text.2
Reminder advertisements that call attention to the name of the product without indications or dosage recommendations are exempt from the brief summary requirement.2 They are limited to the proprietary name, the established name of the product and of each active ingredient and optional items such as dosage form, package contents, price and the firm’s name and address.2 Reminder advertisements other than those conveying price information under § 200.200 are barred for a product whose labeling contains a boxed warning.2
Questions people also ask
What is the difference between a drug’s label and its labeling?
The label is the matter on the container and outer package, and it carries the statement of identity, net quantity, ingredient information, lot number and the prescription legend where applicable.1 Labeling is broader. Section 202.1(l)(2) determines that the following are labeling under section 201(m) of the act when disseminated by or on behalf of the manufacturer.2
- brochures
- detailing pieces
- bulletins
- catalogs
- sound recordings
- exhibits
- literature
- reprints
Which prescription products must use the Highlights of Prescribing Information format?
The format in § 201.56(d) and § 201.57 applies to products with an NDA, BLA or efficacy supplement approved between 30 June 2001 and 30 June 2006, pending on 30 June 2006 or submitted at any time on or after 30 June 2006.1 Products outside those categories follow § 201.56(e) and the older section order in § 201.80.1
May an advertisement promote a use that is supported by published studies but absent from the approved labeling?
An advertisement for a prescription drug covered by an approved NDA, supplement or new animal drug application may not recommend or suggest a use that is not in the labeling accepted in that application.2 Using literature, quotations or references to suggest conditions of use that are not approved or permitted in the package labeling renders the advertisement misleading under § 202.1(e)(6)(xi).2
Does knowledge of off-label prescribing create a new intended use?
Section 201.128 states that a firm would not be regarded as intending an unapproved new use for an approved drug based solely on that firm’s knowledge that the drug was being prescribed or used by health care providers for that use.1 Objective intent is otherwise shown by labeling claims, advertising matter, statements by the firm or its representatives, the design or composition of the article and the circumstances of distribution.1
Which nonprescription products must carry the pregnancy and breast-feeding warning?
All OTC drug products intended for systemic absorption carry the warning in § 201.63(a) unless specifically exempted.1 Drugs intended to benefit the fetus or nursing infant during pregnancy or nursing and drugs labeled exclusively for pediatric use are exempt.1 A specific warning established in an NDA or in a final OTC monograph is used in place of the general warning.1
Who may be named as the manufacturer on a drug label?
Section 201.1(b) defines the manufacturer as the person who performs all of the listed operations required to produce the product, including the following.1
- mixing
- granulating
- milling
- molding
- lyophilizing
- tableting
- encapsulating
- coating
- sterilizing
- filling sterile or aerosol drugs into dispensing containers
Where no single person performs all applicable operations, § 201.1(c) allows other designations. These include a list of joint manufacturers or a breakdown of the form “Made by, Filled by, Sterilized by”.1
Footnotes
-
21 CFR Part 201, Labeling. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46 ↩47 ↩48 ↩49 ↩50 ↩51 ↩52 ↩53 ↩54 ↩55 ↩56 ↩57 ↩58 ↩59 ↩60 ↩61 ↩62 ↩63 ↩64 ↩65 ↩66 ↩67 ↩68 ↩69
-
21 CFR Part 202, Prescription Drug Advertising. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-202 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.